Exelixis Inc. announced preliminary unaudited financial results for fiscal year 2025, reporting approximately $2.123 billion in U.S. net product revenues from its cabozantinib franchise. For fiscal year 2026, the company issued financial guidance projecting net product revenues in the range of $2.325 billion to $2.425 billion. This outlook reflects a significant anticipated increase in business performance compared to the prior year, as Exelixis continues to grow its cabozantinib business and prepares for the potential launch of a second oncology franchise with zanzalintinib.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000939767-26-000003), on January 12, 2026, and is solely responsible for the information contained therein.